Document Detail


A pilot cohort study of granulocyte colony-stimulating factor in the treatment of unresponsive thin endometrium resistant to standard therapies.
MedLine Citation:
PMID:  23081869     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
STUDY QUESTION: Is thin endometrium unresponsive to standard treatments expandable by intrauterine perfusion with granulocyte colony-stimulating factor (G-CSF)?
SUMMARY ANSWER: This cohort study is supportive of the effectiveness of G-CSF in expanding chronically unresponsive endometria.
WHAT IS KNOWN ALREADY: In a previous small case series, we reported the successful off-label use of G-CSF in four consecutive patients, who had previously failed to expand their endometria beyond 6.9 mm with the use of standard treatments.
STUDY DESIGN, SIZE AND DURATION: In a prospective observational cohort pilot study over 18 months, we described 21 consecutive infertile women with endometria <7 mm on the day of hCG administration in their first IVF cycles at our center. All previous cycles using traditional treatments with estradiol, sildenafil citrate (Viagra™) and/or beta-blockers had been unsuccessful. G-CSF (Nupogen™) was administered per intrauterine catheter by slow infusion before noon on the day of hCG administration. If the endometrium had not reached at least a 7-mm within 48h, a second infusion was given following oocyte retrieval. Primary and secondary main outcomes were an increase in endometrial thickness and clinical pregnancy, respectively. Endometrial thickness was assessed by vaginal ultrasound at the most expanded area of the endometrial stripe.
PARTICIPANTS/MATERIALS, SETTINGS AND METHOD: This study was uncontrolled, each patient serving as her own control in a prospective evaluation of endometrial thickness. The mean ± SD age of the cohort was 40.5 ± 6.6 years, gravidity was 1.8 ± 2.1 (range 0-7) and parity was 0.4 ± 1.1 (range 0-4); 76.2% of women had, based on age-specific FSH and anti-Müllerian hormone, an objective diagnosis of diminished ovarian reserve and had failed 2.0 ± 2.1 prior IVF cycles elsewhere.
MAIN RESULTS AND THE ROLE OF CHANCE: With 5.2 ± 1.9 days between G-CSF perfusions and embryo transfers, endometrial thickness increased from 6.4 ± 1.4 to 9.3 ± 2.1 mm (P < 0.001). The Δ in change was 2.9 ± 2.0 mm, and did not vary between conception and non-conception cycles. A 19.1% ongoing clinical pregnancy rate was observed, excluding one ectopic pregnancy.
LIMITATIONS AND REASONS FOR CAUTION: Small sample size (but a highly selected patient population) in an uncontrolled cohort study and in unselected first IVF cycles at our center.
WIDER IMPLICATIONS OF THE FINDINGS: This pilot study supports the utility of G-CSF in the treatment of chronically thin endometrium and suggests that such treatment will, in very adversely affected patients, result in low but very reasonable clinical pregnancy rates.
STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Foundation for Reproductive Medicine, New York, New York, USA, a not-for-profit research foundation and intramural grants from the Center for Human Reproduction (CHR)-New York. N.G. and D.H.B. are members of the board of the Foundation for Reproductive Medicine. N.G. is owner of CHR-New York, where the study was conducted. N.G. and D.H.B. have been recipients of research awards, travel grants and speaker honoraria from various pharmaceutical and medical device companies. None of these companies was, however, in any way associated with the materials and the manuscript presented here. N.G. and D.H.B. are listed as co-inventors on a number of awarded and still pending U.S. patents, none related to the materials presented here. N.G. is on the board of a medically related company, not in any way associated with the data presented here.
Authors:
N Gleicher; A Kim; T Michaeli; H-J Lee; A Shohat-Tal; E Lazzaroni; D H Barad
Related Documents :
23224699 - Is serum placental growth factor more effective as a biomarker in predicting early onse...
24392379 - Evaluation of anaemia in booked antenatal mothers during the last trimester.
12556159 - Placental monocyte infiltrates in response to plasmodium falciparum malaria infection a...
23946909 - Improving the management of an advanced extrauterine pregnancy using pelvic arteriograp...
24293789 - Successful vaginal delivery despite a huge ovarian mucinous cystadenoma complicating pr...
1350539 - Placental malaria and pregnancy outcome.
19422639 - Sports and leisure-time physical activity in pregnancy and birth weight: a population-b...
3712359 - Adenomyosis in pregnancy. a review.
21204609 - Serum activin a levels are lower in tubal than intrauterine spontaneously conceived pre...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-10-18
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  28     ISSN:  1460-2350     ISO Abbreviation:  Hum. Reprod.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-17     Completed Date:  2013-05-29     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  England    
Other Details:
Languages:  eng     Pagination:  172-7     Citation Subset:  IM    
Affiliation:
The Center for Human Reproduction, New York and the Foundation for Reproductive Medicine, New York, NY 10021, USA. ngleicher@thechr.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intravaginal
Adult
Cohort Studies
Drug Monitoring
Drug Resistance*
Endometrium / drug effects*,  pathology
Female
Fertility Agents, Female / administration & dosage,  therapeutic use*
Fertilization in Vitro
Granulocyte Colony-Stimulating Factor / administration & dosage,  therapeutic use*
Humans
Infertility, Female / etiology*,  therapy
Infusions, Parenteral
Middle Aged
New York City / epidemiology
Ovulation Induction
Pilot Projects
Pregnancy
Pregnancy Rate
Primary Ovarian Insufficiency / complications
Prospective Studies
Recombinant Proteins / administration & dosage,  therapeutic use
Uterine Diseases / complications,  drug therapy*,  pathology,  physiopathology
Chemical
Reg. No./Substance:
0/Fertility Agents, Female; 0/Recombinant Proteins; 121181-53-1/Filgrastim; 143011-72-7/Granulocyte Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term reproductive outcomes in women whose first pregnancy is ectopic: a national controlled fol...
Next Document:  Natural therapies assessment for the treatment of endometriosis.